GlycoMimetics Presents Preclinical Data at ASH Annual Meeting Showing GMI-1359 Enhances Efficacy of Chemotherapy in FLT-3 AML Model
IND filing for GMI-1359 planned for mid-2016
"The data presented on GMI-1359 show a dramatic effect on the
development and proliferation of FLT3-ITD AML cells, indicating that
GMI-1359 could serve as an effective method for enhancing chemotherapy
against AML," said
The data obtained from researchers at
GMI-1359 targets both E-selectin, a cell adhesion molecule, and CXCR4, a molecular cytokine. Both of these molecules aid in blood cell resistance to chemotherapy, offering protection to FLT3-mutated cells in the bone marrow. Current therapies can reduce leukemia cell growth in circulating blood of FLT3-mutated AML patients, but do not have any effect on leukemia cells in bone marrow.
The abstract (Abstract #3790), entitled "The Dual E-Selectin/CXCR4 Inhibitor, GMI-1359, Enhances Efficacy of Anti-Leukemia Chemotherapy in FLT3-ITD Mutated Acute Myeloid Leukemia," is available at ASH's website.
GlycoMimetics's wholly-owned drug candidate (GMI-1271) for AML and other
blood disorders is also in clinical trials.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding the
clinical development of the GMI-1359 and the presentation of data.
Actual results may differ materially from those in these forward-looking
statements. For a further description of the risks associated with these
statements, as well as other risks facing
News Provided by Acquire Media